CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ST3GAL2 (ImmuneEditome ID:6483)

1. Gene summary of enriched editing regions for ST3GAL2

check button Gene summary
Gene informationGene symbol

ST3GAL2

Gene ID

6483

GeneSynonymsGal-NAc6S|SIAT4B|ST3GALII|ST3GalA.2
GeneCytomap

16q22.1

GeneTypeprotein-coding
GeneDescriptionCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2|Gal-beta-1,3-GalNAc-alpha-2,3-sialyltransferase|SIAT4-B|ST3Gal II|alpha 2,3-ST 2|beta-galactoside alpha-2,3-sialyltransferase 2|monosialoganglioside sialyltransferase|sialyltransferase 4B (beta-galactosidase alpha-2,3-sialytransferase)
GeneModificationdate20230518
UniprotIDQ16842;A0A024QZA4
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr16:70376724-70378978:-ENST00000393640.7ENSG00000157350.11ST3GAL2UTR3HAL1,AluSp,AluY,AluJr,AluSg7,AluSx,AluSgchr16:70376724-70378978:-.alignment
chr16:70406540-70407463:-ENST00000561708.1ENSG00000157350.11ST3GAL2ncRNA_intronicL2,AluSx,AluSzchr16:70406540-70407463:-.alignment
chr16:70406540-70407463:-ENST00000566097.1ENSG00000157350.11ST3GAL2ncRNA_intronicL2,AluSx,AluSzchr16:70406540-70407463:-.alignment
chr16:70406540-70407463:-ENST00000567586.1ENSG00000157350.11ST3GAL2ncRNA_intronicL2,AluSx,AluSzchr16:70406540-70407463:-.alignment
chr16:70409154-70412593:-ENST00000561708.1ENSG00000157350.11ST3GAL2ncRNA_intronicMLT1L,AluJo,FLAM_C,(T)n,AluJb,AluY,AluSp,AluSx1,L1MEichr16:70409154-70412593:-.alignment
chr16:70409154-70412593:-ENST00000566097.1ENSG00000157350.11ST3GAL2ncRNA_intronicMLT1L,AluJo,FLAM_C,(T)n,AluJb,AluY,AluSp,AluSx1,L1MEichr16:70409154-70412593:-.alignment
chr16:70409154-70412593:-ENST00000567586.1ENSG00000157350.11ST3GAL2ncRNA_intronicMLT1L,AluJo,FLAM_C,(T)n,AluJb,AluY,AluSp,AluSx1,L1MEichr16:70409154-70412593:-.alignment
chr16:70415581-70415989:-ENST00000561708.1ENSG00000157350.11ST3GAL2ncRNA_intronicAluSzchr16:70415581-70415989:-.alignment
chr16:70415581-70415989:-ENST00000566097.1ENSG00000157350.11ST3GAL2ncRNA_intronicAluSzchr16:70415581-70415989:-.alignment
chr16:70415581-70415989:-ENST00000567586.1ENSG00000157350.11ST3GAL2ncRNA_intronicAluSzchr16:70415581-70415989:-.alignment
chr16:70429671-70429887:-ENST00000566097.1ENSG00000157350.11ST3GAL2ncRNA_intronicAluSq2chr16:70429671-70429887:-.alignment
chr16:70429671-70429887:-ENST00000567586.1ENSG00000157350.11ST3GAL2ncRNA_intronicAluSq2chr16:70429671-70429887:-.alignment


Top

2. Tumor-specific enriched editing regions for ST3GAL2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000157350.11,ST3GAL2CESCCliEAG4.7591e-021.5157e-020.4192image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000157350.11,ST3GAL2MESOEAG5.2299e-053.0057e-035.1423e-08image

Top

3. Enriched editing regions and immune related genes for ST3GAL2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr16:70376724-70378978:-DLBCEERENSG00000137309,HMGA10.57252.5930e-023.4806e-050.5759imageNDGCR8;EIF4A3;IGF2BP2;NOP58;TROVE2;UPF1;CSTF2T;DKC1;ELAVL1;NOP56;SRSF3NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V1
chr16:70376724-70378978:-DLBCEERENSG00000196230,TUBB0.55663.6196e-025.4883e-040.4949imageNDGCR8;EIF4A3;IGF2BP2;NOP58;TROVE2;UPF1;CSTF2T;DHX9;DKC1;ELAVL1;NOP56;SRSF3TUBBT_cells_regulatory_(Tregs)GSVA_HALLMARK_E2F_TARGETS
chr16:70376724-70378978:-DLBCEERENSG00000140092,FBLN5-0.53174.6870e-025.4293e-03-0.4078imageNDGCR8;EIF4A3;IGF2BP2;NOP58;UPF1;DKC1;ELAVL1;NOP56;SRSF3FBLN5T_cells_CD4_memory_activatedGSVA_HALLMARK_MYC_TARGETS_V2

More results



Top

4. Enriched editing regions and immune related splicing for ST3GAL2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000157350.11,ST3GAL2
ESCAEAGIRENSG00000101213.5chr2063534151:63534315:63534974:63535059-0.31884.6328e-029.0684e-06-0.4379imageNADAR;CSTF2T;EIF4A3;FAM120A;FBL;FUS;FXR2;GTF2F1;HNRNPA1;NOP56;PTBP1;RBFOX2;SRSF1;TAF15;TARDBP;U2AF2;UPF1NAT_cells_CD4_memory_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
ENSG00000157350.11,ST3GAL2
ESCAEAGIRENSG00000132612.14chr1669321210:69322700:69324207:69325042-0.51152.7336e-043.7890e-07-0.4406imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184VPS4AT_cells_CD4_memory_restingGSVA_HALLMARK_HYPOXIA
ENSG00000157350.11,ST3GAL2
ESCAEAGIRENSG00000164543.5chr743619596:43623888:43624517:43625184-0.46681.7829e-036.0699e-07-0.4336imageNACIN1;ADAR;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184STK17AT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
ENSG00000157350.11,ST3GAL2
ESCAEAGIRENSG00000214021.11chr39817644:9817759:9818821:9818871-0.31842.8624e-027.7035e-05-0.4023imageNADAR;AIFM1;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184NAMacrophages_M2GSVA_HALLMARK_APICAL_JUNCTION
ENSG00000157350.11,ST3GAL2
ESCAEAGESENSG00000165097.9chr618200438:18200576:18201485:18201657:18205536:18205664-0.36352.4724e-025.4778e-06-0.4016imageNACIN1;ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NAMast_cells_restingGSVA_HALLMARK_PEROXISOME
ENSG00000157350.11,ST3GAL2
ESCAEAGIRENSG00000164543.5chr743619596:43619723:43623571:43623617-0.45212.9678e-034.4463e-06-0.4020imageNACIN1;ADAR;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184STK17AT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
ENSG00000157350.11,ST3GAL2
TGCTEAGA3ENSG00000111704.6chr127788418:7788574:7789630:7789765:7789619:77897650.28631.6732e-022.4892e-050.4332imageNADAR;EIF4A3;ELAVL1;EWSR1;FBL;FUS;HNRNPA1;HNRNPL;IGF2BP2;IGF2BP3;LIN28A;RBFOX2;SRSF1;TAF15;TARDBP;U2AF2NAT_cells_follicular_helperGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000157350.11,ST3GAL2
TGCTEAGIRENSG00000103275.14chr161312184:1312603:1314019:1314032-0.35555.7398e-034.4792e-06-0.4131imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAB_cells_naiveGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr16:70376724-70378978:-
TGCTEERESENSG00000141127.10chr1718858185:18858261:18865468:18865564:18865801:18865900-0.29321.3011e-022.6336e-05-0.4190imageNDGCR8;EIF4A3;IGF2BP2;NOP58;TROVE2;UPF1;CSTF2T;DHX9;DKC1;ELAVL1;NOP56;SRSF3NAT_cells_CD8GSVA_HALLMARK_MYC_TARGETS_V1
ENSG00000157350.11,ST3GAL2
TGCTEAGESENSG00000141127.10chr1718858185:18858261:18865468:18865564:18865801:18865900-0.29271.2315e-022.6336e-05-0.4190imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_CD8GSVA_HALLMARK_MYC_TARGETS_V1

More results



Top

5. Enriched editing regions and immune infiltration for ST3GAL2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000157350.11,ST3GAL2ACCEAGB_cells_naive9.7752e-03-0.4140image
ENSG00000157350.11,ST3GAL2CESCEAGT_cells_regulatory_(Tregs)1.8974e-020.4003image
ENSG00000157350.11,ST3GAL2COADEAGMacrophages_M22.6331e-020.2565image
chr16:70376724-70378978:-DLBCEEREosinophils3.8622e-030.4222image
ENSG00000157350.11,ST3GAL2DLBCEAGEosinophils2.6581e-030.4374image
chr16:70376724-70378978:-ESCAEERMacrophages_M01.0946e-020.2451image
chr16:70409154-70412593:-ESCAEERMonocytes1.5142e-02-0.3001image
ENSG00000157350.11,ST3GAL2ESCAEAGT_cells_CD4_memory_resting2.0059e-02-0.2103image
chr16:70376724-70378978:-HNSCEERT_cells_gamma_delta4.1452e-030.4106image
ENSG00000157350.11,ST3GAL2HNSCEAGT_cells_gamma_delta4.1452e-030.4106image
chr16:70376724-70378978:-KIRCEERDendritic_cells_activated9.2667e-040.2441image
ENSG00000157350.11,ST3GAL2KIRCEAGDendritic_cells_activated4.6195e-030.2091image
chr16:70376724-70378978:-KIRPEERMacrophages_M13.5251e-02-0.2419image
ENSG00000157350.11,ST3GAL2KIRPEAGMacrophages_M13.0653e-02-0.2482image
chr16:70376724-70378978:-LAMLEERT_cells_gamma_delta2.9449e-02-0.2106image
chr16:70409154-70412593:-LAMLEERPlasma_cells2.3953e-020.2304image
ENSG00000157350.11,ST3GAL2LAMLEAGT_cells_CD4_naive4.9615e-02-0.1732image
ENSG00000157350.11,ST3GAL2LGGEAGMast_cells_activated1.2279e-020.1786image
ENSG00000157350.11,ST3GAL2LUADEAGDendritic_cells_activated7.7116e-030.2528image
chr16:70376724-70378978:-OVEERMacrophages_M01.9115e-02-0.1681image
ENSG00000157350.11,ST3GAL2OVEAGMacrophages_M01.5505e-02-0.1718image
chr16:70376724-70378978:-PCPGEERT_cells_gamma_delta1.7345e-030.3035image
ENSG00000157350.11,ST3GAL2PCPGEAGT_cells_gamma_delta1.7220e-030.3037image
ENSG00000157350.11,ST3GAL2PRADEAGMast_cells_activated2.9110e-030.5168image
ENSG00000157350.11,ST3GAL2READEAGT_cells_CD4_naive4.8166e-030.4858image
chr16:70376724-70378978:-SKCMEERMacrophages_M22.7715e-03-0.1748image
ENSG00000157350.11,ST3GAL2SKCMEAGMacrophages_M22.8374e-03-0.1744image
chr16:70376724-70378978:-STADEERB_cells_naive8.1882e-03-0.1662image
chr16:70406540-70407463:-STADEERT_cells_follicular_helper2.5898e-020.3874image
chr16:70376724-70378978:-TGCTEERT_cells_follicular_helper1.3119e-030.2821image
ENSG00000157350.11,ST3GAL2TGCTEAGT_cells_follicular_helper2.9912e-030.2614image
chr16:70376724-70378978:-THCAEERPlasma_cells4.4079e-020.1675image
ENSG00000157350.11,ST3GAL2THCAEAGPlasma_cells4.4079e-020.1675image
ENSG00000157350.11,ST3GAL2UCECEAGNeutrophils7.2640e-040.4057image
chr16:70376724-70378978:-UCSEERB_cells_memory4.7968e-020.2932image
ENSG00000157350.11,ST3GAL2UCSEAGB_cells_memory4.8420e-020.2926image


Top

6. Enriched editing regions and immune gene sets for ST3GAL2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr16:70376724-70378978:-STADEER2.0255e-05image3.2026e-030.1850image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr16:70376724-70378978:-STADEER3.3855e-040.22401.0154e-020.16171.9675e-030.19417.8431e-060.2774image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000157350.11,ST3GAL2BLCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG6.5999e-030.2336image
chr16:70376724-70378978:-BLCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER4.3747e-040.3040image
ENSG00000157350.11,ST3GAL2BRCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG6.2465e-030.1895image
chr16:70376724-70378978:-BRCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER2.0190e-030.2160image
ENSG00000157350.11,ST3GAL2CESCGSVA_HALLMARK_ANGIOGENESISEAG1.9897e-02-0.3975image
ENSG00000157350.11,ST3GAL2COADGSVA_HALLMARK_DNA_REPAIREAG2.3966e-03-0.3455image
chr16:70376724-70378978:-DLBCGSVA_HALLMARK_SPERMATOGENESISEER3.3460e-020.3177image
ENSG00000157350.11,ST3GAL2DLBCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG2.2635e-020.3392image
chr16:70376724-70378978:-ESCAGSVA_HALLMARK_MYOGENESISEER2.5824e-030.2885image
ENSG00000157350.11,ST3GAL2ESCAGSVA_HALLMARK_HYPOXIAEAG9.1662e-040.2964image
ENSG00000157350.11,ST3GAL2GBMGSVA_HALLMARK_ANDROGEN_RESPONSEEAG4.4525e-030.2794image
ENSG00000157350.11,ST3GAL2HNSCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG4.1639e-020.2984image
chr16:70376724-70378978:-HNSCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER4.1639e-020.2984image
chr16:70376724-70378978:-LAMLGSVA_HALLMARK_SPERMATOGENESISEER2.3480e-020.2189image
ENSG00000157350.11,ST3GAL2LGGGSVA_HALLMARK_UV_RESPONSE_DNEAG9.0531e-050.2759image
ENSG00000157350.11,ST3GAL2LIHCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.0979e-020.2927image
chr16:70376724-70378978:-LIHCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.1384e-020.2736image
ENSG00000157350.11,ST3GAL2LUSCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG9.2601e-030.3180image
chr16:70376724-70378978:-LUSCGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.1134e-020.3106image
ENSG00000157350.11,ST3GAL2OVGSVA_HALLMARK_P53_PATHWAYEAG2.4915e-050.2948image
chr16:70376724-70378978:-OVGSVA_HALLMARK_P53_PATHWAYEER6.4476e-050.2828image
chr16:70409154-70412593:-OVGSVA_HALLMARK_UV_RESPONSE_DNEER3.2697e-030.3543image
chr16:70376724-70378978:-PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.8256e-030.2744image
ENSG00000157350.11,ST3GAL2PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.6266e-030.2756image
ENSG00000157350.11,ST3GAL2PRADGSVA_HALLMARK_DNA_REPAIREAG1.3727e-02-0.4380image
chr16:70376724-70378978:-SARCGSVA_HALLMARK_PEROXISOMEEER2.2129e-030.2410image
ENSG00000157350.11,ST3GAL2SARCGSVA_HALLMARK_PEROXISOMEEAG1.9659e-030.2429image
ENSG00000157350.11,ST3GAL2SKCMGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.1915e-020.1472image
chr16:70376724-70378978:-SKCMGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.1674e-020.1477image
chr16:70409154-70412593:-STADGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.6304e-030.2779image
ENSG00000157350.11,ST3GAL2STADGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG2.9078e-090.3551image
chr16:70376724-70378978:-STADGSVA_HALLMARK_P53_PATHWAYEER1.7953e-100.3879image
ENSG00000157350.11,ST3GAL2TGCTGSVA_HALLMARK_MYC_TARGETS_V2EAG1.1407e-030.2855image
chr16:70376724-70378978:-TGCTGSVA_HALLMARK_MYC_TARGETS_V2EER1.3396e-030.2816image
chr16:70376724-70378978:-THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.3293e-020.2052image
ENSG00000157350.11,ST3GAL2THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.3293e-020.2052image
ENSG00000157350.11,ST3GAL2UCECGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG2.1996e-020.2816image
chr16:70376724-70378978:-UCSGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.2144e-02-0.3669image
ENSG00000157350.11,ST3GAL2UCSGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG1.1534e-02-0.3693image


Top

7. Enriched editing regions and drugs for ST3GAL2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000157350.11,ST3GAL2ACCGSK.650394EAG4.1936e-020.3317image
ENSG00000157350.11,ST3GAL2BLCABIRB.0796EAG7.5360e-030.2299image
chr16:70376724-70378978:-BLCAATRAEER3.6548e-030.2532image
chr16:70376724-70378978:-BRCALapatinibEER2.1593e-04-0.2581image
ENSG00000157350.11,ST3GAL2BRCALapatinibEAG5.8658e-04-0.2375image
ENSG00000157350.11,ST3GAL2CESCAxitinibEAG4.5430e-030.4749image
chr16:70376724-70378978:-COADCisplatinEER1.4511e-02-0.2953image
ENSG00000157350.11,ST3GAL2COADBMS.708163EAG1.0977e-03-0.3697image
chr16:70376724-70378978:-DLBCBI.2536EER8.5553e-04-0.4797image
ENSG00000157350.11,ST3GAL2DLBCBI.2536EAG7.3855e-04-0.4848image
chr16:70409154-70412593:-ESCABMS.708163EER6.2285e-03-0.3359image
chr16:70376724-70378978:-ESCAGNF.2EER3.4800e-05-0.3889image
ENSG00000157350.11,ST3GAL2ESCAGNF.2EAG2.0513e-04-0.3300image
ENSG00000157350.11,ST3GAL2GBMAMG.706EAG3.1452e-040.3497image
ENSG00000157350.11,ST3GAL2HNSCMethotrexateEAG8.3542e-03-0.3844image
chr16:70376724-70378978:-HNSCMethotrexateEER8.3542e-03-0.3844image
chr16:70376724-70378978:-KIRCBMS.708163EER1.5425e-02-0.1798image
ENSG00000157350.11,ST3GAL2KIRCBMS.708163EAG6.3191e-03-0.2017image
chr16:70376724-70378978:-KIRPBMS.754807EER1.0220e-02-0.2930image
ENSG00000157350.11,ST3GAL2KIRPBMS.754807EAG1.5890e-02-0.2758image
chr16:70376724-70378978:-LAMLA.770041EER1.1927e-02-0.2423image
ENSG00000157350.11,ST3GAL2LAMLAICAREAG1.8775e-020.2067image
ENSG00000157350.11,ST3GAL2LGGKIN001.135EAG1.5596e-03-0.2245image
ENSG00000157350.11,ST3GAL2LIHCGW.441756EAG5.4347e-03-0.3490image
chr16:70376724-70378978:-LIHCGW.441756EER1.0939e-03-0.4050image
chr16:70376724-70378978:-LUSCAxitinibEER3.3553e-02-0.2620image
ENSG00000157350.11,ST3GAL2LUSCJNJ.26854165EAG3.1076e-02-0.2657image
chr16:70376724-70378978:-OVAG.014699EER9.6615e-030.1854image
chr16:70409154-70412593:-OVAP.24534EER2.1741e-02-0.2800image
ENSG00000157350.11,ST3GAL2OVAG.014699EAG7.4800e-030.1896image
ENSG00000157350.11,ST3GAL2PAADCamptothecinEAG2.0090e-020.3709image
chr16:70376724-70378978:-PCPGGSK269962AEER1.0540e-020.2498image
ENSG00000157350.11,ST3GAL2PCPGAG.014699EAG1.0401e-020.2503image
ENSG00000157350.11,ST3GAL2PRADBMS.708163EAG1.4389e-03-0.5473image
ENSG00000157350.11,ST3GAL2READBMS.536924EAG2.3859e-020.4049image
chr16:70376724-70378978:-SARCAG.014699EER9.3176e-050.3049image
ENSG00000157350.11,ST3GAL2SARCAG.014699EAG1.6826e-040.2932image
chr16:70376724-70378978:-SKCMCGP.082996EER7.3303e-04-0.1969image
ENSG00000157350.11,ST3GAL2SKCMCGP.082996EAG4.6629e-03-0.1654image
chr16:70409154-70412593:-STADABT.263EER1.9726e-020.2075image
chr16:70406540-70407463:-STADAZD.2281EER5.0103e-05-0.6454image
ENSG00000157350.11,ST3GAL2STADCCT007093EAG8.7352e-030.1611image
chr16:70376724-70378978:-STADCCT007093EER3.2203e-040.2248image
ENSG00000157350.11,ST3GAL2TGCTKU.55933EAG2.8324e-05-0.3624image
chr16:70376724-70378978:-TGCTKU.55933EER2.8173e-05-0.3625image
ENSG00000157350.11,ST3GAL2THCAKU.55933EAG5.0438e-03-0.2317image
chr16:70376724-70378978:-THCAKU.55933EER5.0438e-03-0.2317image
ENSG00000157350.11,ST3GAL2UCECLenalidomideEAG3.5348e-02-0.2595image
chr16:70376724-70378978:-UCSCCT018159EER3.8095e-02-0.3068image
ENSG00000157350.11,ST3GAL2UCSCCT018159EAG3.5998e-02-0.3101image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType